Ovarian Cancer Clinical Trials

Showing 801-820 of 1,019 trials

Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse

NCT00437307

Determination of progression free survival after 12 months of FU Determination of total survival, response and quality of life

Ovarian Cancer

North Eastern German Society of Gynaecological Oncology550 participantsStarted Mar 2007

Berlin, Germany

COMPLETEDPhase 1

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

NCT01209195

This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.

Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,Primary Peritoneal Cancer or Endometrial CancerLocally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer

Merrimack Pharmaceuticals41 participantsStarted Oct 2010

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Bakersfield, California, United States +2 more locations

COMPLETEDPhase 2

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

NCT01031381

This study will investigate the efficacy as well as the safety of RAD001 in combination with bevacizumab for recurrent ovarian, peritoneal, and fallopian tube cancer. RAD001 will be taken orally once daily and bevacizumab will be administered once every 14 days. The study will be conducted over a period of about 3 to 4 years.

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma

University of Pittsburgh50 participantsStarted Sep 2010

Pittsburgh, Pennsylvania, United States

Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

Related Searches

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

Genetic Counseling in African American Women

Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission

Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer

LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Total/Subtotal Colectomy in Ovarian Cancer

Tumor Gene Expression in Women With Ovarian Cancer

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Cancer Prevention in Women With a BRCA Mutation

Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression

Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy